Epilepsy - Market Insight, Epidemiology and Market Forecast -2027

DelveInsight Business Research LLP


Albany, NY -- (SBWire) -- 10/22/2018 --DelveInsight has announced the addition of the "Epilepsy - Market Insight, Epidemiology and Market Forecast -2027" drug pipelines to their offering.

The report provides an overview of the disease and market size of Epilepsy for 7MM. The Report covers the overview, treatment practice and Epilepsy forecasted epidemiology from 2018 to 2027 segmented by seven major markets.

Request for sample pages: https://www.delveinsight.com/dev-sample.php?form_name=Epilepsy---Market-Insight,-Epidemiology-and-Market-Forecast---2027

Epilepsy is a condition that develops as a result of abnormal activity in the brain. Regular brain activity occurs through electrical signals that pass between cells in the brain called neurons. Usually these signals are passed from cell to cell in a systematic and controlled way, which results in all of a person's thoughts and feelings. As per WHO, Epilepsy is a disorder that can occur in all mammalian species. The periodic clinical features of seizures are often dramatic and alarming, and frequently elicit fear and misunderstanding. This in turn has led to profound social consequences for sufferers, which has greatly added to the burden of this disease.

As per DelveInsight's analysis, there were a total of 4,007,026 Epilepsy prevalent cases in 2016 which are expected to increase for the study period 2016-2027. Epilepsy is found to be highly prevalent in the United States as the prevalence is between 5-8.4/1000 persons per year or approximately 1% of the population. As per DelveInsight's analysis, the male prevalent population of epilepsy was at 2,137,080 and the female prevalent population was at 1,869,945 in 2016. There were about 24,46,534 prevalent cases of Focal/Partial Epilepsy, 12,36,491 cases of generalized epilepsy and 3,24,000 cases of unclassified epilepsy in 2016, as per DelveInsight analysis. As per DelveInsight's estimation, the market size of Epilepsy in the United States was USD 3.9 bn in 2016, which is expected to increase up to the year 2027.

Geography Covered
1. The United States
2. EU5 (Germany, France, Italy, Spain and the United Kingdom)
3. Japan
Study Period: 2016-2027

Epilepsy Drug Companies

1. GW PHarma
2. Catalent Pharma
3. Eisai Pharmaceuticals
4. Sunovion Pharmaceuticals
And many others

Drugs covered
1. Epidiolex
2. Trokendi XR
3. Fycompa
4. Aptiom
And many others

Report Scope

The report covers a descriptive overview of the Epilepsy, explaining its causes and currently available therapies. Comprehensive insight has been provided into the epidemiology of the Epilepsy and its treatment in covering the 7MM covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan. Additionally, an all-inclusive account of both the current and emerging therapies for Epilepsy are provided, along with assessment of the impact of new therapies will have on the current treatment landscape. A detailed review of historical and forecasted Epilepsy market is included in the report, covering drug outreach in 7MM. The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Epilepsy market.

Media Relations Contact

Ankit Nigam

View this press release online at: http://rwire.com/1069860